Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Therapeutics announced Phase 3 trial results of ALXN1840 demonstrating greater neurologic improvement and reduced deterioration in Wilson disease patients with neurologic symptoms, compared to standard of care. The drug showed sustained benefits over multiple years and a favorable safety profile, supporting an FDA NDA submission planned for…